Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

Five months af­ter their lead drug failed to treat schiz­o­phre­nia in a Phase III tri­al, Aca­dia is tout­ing just-bare­ly sig­nif­i­cant da­ta that sug­gest it could help im­prove a sub­set of the ill­ness’s symp­toms.

The 201 pa­tients giv­en Aca­dia’s Nu­plazid earned a -10.4 on the Neg­a­tive Symp­tom As­sess­ment-16 test, against a -8.5 score for the 202 place­bo pa­tients. The p-val­ue was 0.043, and the Phase II tri­al failed on the sec­ondary end­point: An­oth­er psy­cho­log­i­cal as­sess­ment called the Per­son­al and So­cial Per­for­mance (PSP).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.